BioNTech SE (BNTX) Non-Current Deferred Tax Liability (2020 - 2026)

BioNTech SE has reported Non-Current Deferred Tax Liability for 6 years, with the latest figure at $98.1 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 116.58% year-over-year to $98.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $98.1 million (up 116.58% YoY) and the FY2025 annual result came in at $95.2 million, up 110.21% from the prior year.
• Non-Current Deferred Tax Liability advanced to $98.1 million in Q4 2025 per BNTX's latest filing, from $28.3 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $107.1 million in Q2 2022 and troughed at $4.9 million in Q2 2023.
• A 5-year average of $42.9 million and a median of $42.7 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deferred Tax Liability soared 31898.45% in 2021, then plunged 95.43% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $76.3 million in 2021, then slumped by 91.71% to $6.3 million in 2022, then soared by 575.28% to $42.7 million in 2023, then increased by 6.07% to $45.3 million in 2024, then jumped by 116.58% to $98.1 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $98.1 million, $28.3 million, and $32.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.